Prof. Dr. Giuseppe Curigliano, on behalf of Philogen, is giving a presentation about the Phase I DODEKA study on February 26th, entitled “Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors”.
Dr. Jacqueline Mock is presenting a poster about Philochem’s new small molecule drug conjugate on February 26th, entitled “Optimisation of FAP-targeted small molecule drug conjugates for the delivery and release of cytotoxic payloads in solid tumors”
Follow the link for more details.